Alveena Younas
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Alveena Younas has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Dilshad Ahmed Khan
Armed Forces Institute of Pathology, National University of Medical Sciences, Rawalpindi 46000, Pakistan
1 shared publication - Muhammad Amjad Pervez
Armed Forces Institute of Pathology, National University of Medical Sciences, Rawalpindi 46000, Pakistan
1 shared publication - Muhammad Qaiser Alam Khan
Armed Forces Institute of Pathology, National University of Medical Sciences, Rawalpindi 46000, Pakistan
1 shared publication - Nayyar Chaudhry
Armed Forces Institute of Pathology, National University of Medical Sciences, Rawalpindi 46000, Pakistan
1 shared publication - Sumbal Nida
Armed Forces Institute of Pathology, National University of Medical Sciences, Rawalpindi 46000, Pakistan
1 shared publication
Latest Publications
- Open Access
- 4 March 2026
- Published by MDPI AG in Current Issues in Molecular Biology
- Vol. 48 (3) , 272
Circulating MicroRNA Profiling for Phenotypic Stratification in Patients with Metabolic Dysfunction-Associated Fatty Liver Disease: A Candidate-Based Study
Metabolic dysfunction-associated fatty liver disease (MAFLD) comprises phenotypic subgroups, including type-2 diabetes-associated MAFLD (T2D-MAFLD), obesity-associated MAFLD (OB-MAFLD), and lean MAFLD (L-MAFLD). Emerging evidence indicates that dysregulation of miRNAs plays a key role in MAFLD pathogenesis and progression. This study evaluated the diagnostic accuracy of a plasma miRNA-based signature as a non-invasive biomarker for early detection and phenotypic stratification of MAFLD. A total of 393 MAFLD patients and 109 healthy controls were enrolled. Plasma expression of miR-122, miR-103a, miR-222, miR-15a, miR-34a, miR-192, miR-197, and miR-99a was quantified using Reverse transcription polymerase chain reaction. Compared to controls, MAFLD patients exhibited significant upregulation of miR-122, miR-103a, miR-222, miR-15a, and miR-34a, alongside downregulation of miR-197 and miR-99a. Multinomial logistic regression revealed phenotype-specific associations: miR-103a, miR-34a, and miR-197 with T2D-MAFLD; miR-122, miR-222, and miR-99a with OB-MAFLD; and miR-15a with L-MAFLD. Receiver operating characteristic analysis demonstrated highest individual diagnostic accuracy for miR-197 in T2D-MAFLD (AUC = 0.784), miR-99a in OB-MAFLD (AUC = 0.869), and miR-15a in L-MAFLD (AUC = 0.776). Integrating combined miRNA panels with biochemical markers further improved diagnostic performance and clinical utility, achieving high positive and negative predictive values. In conclusion, plasma miRNA signatures enable phenotype-specific discrimination of MAFLD subtypes and may serve as promising non-invasive tools pending multi-center validation.
- 4 March 2026
- Published by MDPI AG in Current Issues in Molecular Biology
- Vol. 48 (3) , 272
Open AccessCirculating MicroRNA Profiling for Phenotypic Stratification in Patients with Metabolic Dysfunction-Associated Fatty Liver Disease: A Candidate-Based Study
Metabolic dysfunction-associated fatty liver disease (MAFLD) comprises phenotypic subgroups, including type-2 diabetes-associated MAFLD (T2D-MAFLD), obesity-associated MAFLD (OB-MAFLD), and lean MAFLD (L-MAFLD). Emerging evidence indicates that dysregulation of miRNAs plays a key role in MAFLD pathogenesis and progression. This study evaluated the diagnostic accuracy of a plasma miRNA-based signature as a non-invasive biomarker for early detection and phenotypic stratification of MAFLD. A total of 393 MAFLD patients and 109 healthy controls were enrolled. Plasma expression of miR-122, miR-103a, miR-222, miR-15a, miR-34a, miR-192, miR-197, and miR-99a was quantified using Reverse transcription polymerase chain reaction. Compared to controls, MAFLD patients exhibited significant upregulation of miR-122, miR-103a, miR-222, miR-15a, and miR-34a, alongside downregulation of miR-197 and miR-99a. Multinomial logistic regression revealed phenotype-specific associations: miR-103a, miR-34a, and miR-197 with T2D-MAFLD; miR-122, miR-222, and miR-99a with OB-MAFLD; and miR-15a with L-MAFLD. Receiver operating characteristic analysis demonstrated highest individual diagnostic accuracy for miR-197 in T2D-MAFLD (AUC = 0.784), miR-99a in OB-MAFLD (AUC = 0.869), and miR-15a in L-MAFLD (AUC = 0.776). Integrating combined miRNA panels with biochemical markers further improved diagnostic performance and clinical utility, achieving high positive and negative predictive values. In conclusion, plasma miRNA signatures enable phenotype-specific discrimination of MAFLD subtypes and may serve as promising non-invasive tools pending multi-center validation.